Mohammad Haris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mohammad Haris has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Anup Singh
Centre for Biomedical Engineering, Indian Institute of Technology Delhi, New Delhi, India
3 shared publications - Ravinder Reddy
Center for Advanced Metabolic Imaging in Precision Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, PA, United States
3 shared publications Elias R. Melhem
Neuroradiology, Department of Radiology University of Pennsylvania Philadelphia PA USA
2 shared publications- Hari Hariharan
Center for Magnetic Resonance and Optical Imaging, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
2 shared publications Kejia Cai
Center for Magnetic Resonance and Optical Imaging, Department of Radiology University of Pennsylvania Philadelphia PA USA
2 shared publicationsArijitt Borthakur
From the CMROI (MH, AS, KC, EM, MF, RR, AB); SBIA (CD); Center for Neurodegenerative Disease Research Department of Radiology (ERM); and Department of Neurology, University of Pennsylvania, Philadelphia, PA (CMC)
1 shared publication
Latest Publications
- Open Access
- 21 March 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 97
Imaging technologies from bench to bedside
- 21 March 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 97
Open AccessImaging technologies from bench to bedside
- 3 April 2013
- Published by Wiley in NMR in Biomedicine
- Vol. 26 (10) , 1278-1284
Mapping glutamate in subcortical brain structures using high‐resolution GluCEST MRI
In vivo measurement of glutamate (Glu) in brain subcortex can elucidate the role these structures play in cognition and neuropsychiatric disorders. However, accurate quantification of Glu in subcortical regions is challenging. Recently, a novel MRI method based on the Glu chemical exchange saturation transfer (GluCEST) effect has been developed for detecting brain Glu in millimolar concentrations. Here, we use GluCEST to map Glu distributions in subcortical structures of the human brain (e.g. amygdala, hippocampus). Overall, GluCEST was ~40% higher in gray matter than in white matter. Within the subcortical gray matters, amygdala showed the highest GluCEST contrast. Utilizing MR spectroscopic data, in vivo GluCEST detection sensitivity (~0.8% mM−1) in subcortical gray matter was evaluated and was consistent with the previously reported values. In general, the GluCEST map approximates the Glu receptor distribution reported in previous positron emission tomography (PET) studies. These findings suggest that high‐resolution GluCEST MRI of subcortical brain structures may prove to be a useful tool in diagnosis of brain disorders or treatment responses. Copyright © 2013 John Wiley & Sons, Ltd.
- 3 April 2013
- Published by Wiley in NMR in Biomedicine
- Vol. 26 (10) , 1278-1284
Mapping glutamate in subcortical brain structures using high‐resolution GluCEST MRI
In vivo measurement of glutamate (Glu) in brain subcortex can elucidate the role these structures play in cognition and neuropsychiatric disorders. However, accurate quantification of Glu in subcortical regions is challenging. Recently, a novel MRI method based on the Glu chemical exchange saturation transfer (GluCEST) effect has been developed for detecting brain Glu in millimolar concentrations. Here, we use GluCEST to map Glu distributions in subcortical structures of the human brain (e.g. amygdala, hippocampus). Overall, GluCEST was ~40% higher in gray matter than in white matter. Within the subcortical gray matters, amygdala showed the highest GluCEST contrast. Utilizing MR spectroscopic data, in vivo GluCEST detection sensitivity (~0.8% mM−1) in subcortical gray matter was evaluated and was consistent with the previously reported values. In general, the GluCEST map approximates the Glu receptor distribution reported in previous positron emission tomography (PET) studies. These findings suggest that high‐resolution GluCEST MRI of subcortical brain structures may prove to be a useful tool in diagnosis of brain disorders or treatment responses. Copyright © 2013 John Wiley & Sons, Ltd.
- 9 October 2012
- Published by Wiley in NMR in Biomedicine
- Vol. 26 (4) , 386-391
Imaging of glutamate neurotransmitter alterations in Alzheimer's disease
Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP‐PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild‐type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through 1H MRS. A positive correlation was observed between GluCEST contrast and 1H MRS‐measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease‐modifying therapies for AD. Copyright © 2012 John Wiley & Sons, Ltd.
- 9 October 2012
- Published by Wiley in NMR in Biomedicine
- Vol. 26 (4) , 386-391
Imaging of glutamate neurotransmitter alterations in Alzheimer's disease
Glutamate (Glu) is a major excitatory neurotransmitter in the brain and has been shown to decrease in the early stages of Alzheimer's disease (AD). Using a glutamate chemical (amine) exchange saturation transfer (GluCEST) method, we imaged the change in [Glu] in the APP‐PS1 transgenic mouse model of AD at high spatial resolution. Compared with wild‐type controls, AD mice exhibited a notable reduction in GluCEST contrast (~30%) in all areas of the brain. The change in [Glu] was further validated through 1H MRS. A positive correlation was observed between GluCEST contrast and 1H MRS‐measured Glu/total creatine ratio. This method potentially provides a novel noninvasive biomarker for the diagnosis of the disease in preclinical stages and enables the development of disease‐modifying therapies for AD. Copyright © 2012 John Wiley & Sons, Ltd.
- 24 March 2011
- Published by Wiley in Journal of Neuroimaging
- Vol. 21 (2) , e86-e90
T1ρ MRI in Alzheimer's Disease: Detection of Pathological Changes in Medial Temporal Lobe
BACKGROUND The need of an early and noninvasive diagnosis of AD requires the development of imaging‐based techniques. As an alternative, the magnetic resonance image (MRI) relaxation time constant (T1ρ) was measured in brains of Alzheimer's disease (AD), mild‐cognitive impairment (MCI), and age‐matched controls in order to determine whether T1ρ values correlated with the neurological diagnosis. METHODS MRI was performed on AD (n= 48), MCI (n= 45), and age‐matched control (n= 41), on a 1.5 Tesla Siemens clinical MRI scanner. T1ρ maps were generated by fitting each pixel's intensity as a function of the duration of the spin‐lock pulse. T1ρ values were calculated from the gray matter (GM) and white matter (WM) of medial temporal lobe (MTL). RESULTS GM and WM T1ρ values were 87.5 ± 1.2 ms and 80.5 ± 1.4 ms, respectively, in controls, 90.9 ± 1.3 ms and 84.1 ± 1.7 ms in MCI, and 91.9 ± .8 ms and 88.3 ± 1.3 ms in AD cohorts. Compared to control, AD patients showed 9% increased WM T1ρ and 5% increased GM T1ρ. Compared to control, MCI individuals showed 4% increased T1ρ both in WM and GM. A 5% increased T1ρ was found in WM of AD over MCI. CONCLUSION The increased T1ρ in WM and GM of MTL in AD may be associated with the pathological changes that are not evident on conventional MRI.
- 24 March 2011
- Published by Wiley in Journal of Neuroimaging
- Vol. 21 (2) , e86-e90
T1ρ MRI in Alzheimer's Disease: Detection of Pathological Changes in Medial Temporal Lobe
BACKGROUND The need of an early and noninvasive diagnosis of AD requires the development of imaging‐based techniques. As an alternative, the magnetic resonance image (MRI) relaxation time constant (T1ρ) was measured in brains of Alzheimer's disease (AD), mild‐cognitive impairment (MCI), and age‐matched controls in order to determine whether T1ρ values correlated with the neurological diagnosis. METHODS MRI was performed on AD (n= 48), MCI (n= 45), and age‐matched control (n= 41), on a 1.5 Tesla Siemens clinical MRI scanner. T1ρ maps were generated by fitting each pixel's intensity as a function of the duration of the spin‐lock pulse. T1ρ values were calculated from the gray matter (GM) and white matter (WM) of medial temporal lobe (MTL). RESULTS GM and WM T1ρ values were 87.5 ± 1.2 ms and 80.5 ± 1.4 ms, respectively, in controls, 90.9 ± 1.3 ms and 84.1 ± 1.7 ms in MCI, and 91.9 ± .8 ms and 88.3 ± 1.3 ms in AD cohorts. Compared to control, AD patients showed 9% increased WM T1ρ and 5% increased GM T1ρ. Compared to control, MCI individuals showed 4% increased T1ρ both in WM and GM. A 5% increased T1ρ was found in WM of AD over MCI. CONCLUSION The increased T1ρ in WM and GM of MTL in AD may be associated with the pathological changes that are not evident on conventional MRI.